Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 6/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904335 | 0.89 | SCN9A (0.48) | SCN9AHTR2ACYP3A4CYP2C19CYP2C9 | |
| SCHEMBL5517804 | 0.89 | HTR2A (0.52) | SCN9AHTR2ACYP3A4CYP2C19CYP2C9 | |
| SCHEMBL13006934 | 0.81 | SCN9A (0.49) | SCN9AHTR2ACYP3A4CYP2C19CYP2C9 | |
| SCHEMBL10063545 | 0.81 | SCN9A (0.42) | SCN9ACYP3A4CYP2C19CYP2C9CYP2D6 | |
| SCHEMBL4431910 | 0.81 | CYP3A4 (0.58) | SCN9AHTR2ACYP3A4CYP2C19CYP2C9 | |
| SCHEMBL6368381 | 0.80 | SCN9A (0.48) | SCN9AHTR2ACYP3A4CYP2C19CYP2C9 | |
| SCHEMBL4431788 | 0.80 | CYP3A4 (0.60) | SCN9AHTR2ACYP3A4CYP2C19CYP2C9 | |
| SCHEMBL1260727 | 0.80 | CYP3A4 (0.61) | SCN9ACYP3A4CYP2C19CYP2C9CYP2D6 | |
| SCHEMBL14452260 | 0.79 | CYP3A4 (0.59) | SCN9AHTR2ACYP3A4CYP2C19CYP2C9 | |
| SCHEMBL1261240 | 0.79 | CYP3A4 (0.62) | SCN9ACYP3A4CYP2C19CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135949-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| WO-2012044520-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
| WO-2007019674-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135949-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | HAVCR2, EIF2AK2, SLC10A1 | SCN9A 3837/4885HTR2A 4114/4885CYP3A4 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.